Ignite Creation Date:
2024-05-05 @ 11:33 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00077779
Status:
COMPLETED
Last Update Posted:
2007-09-26
First Post:
2004-02-12
Brief Title:
Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohns Disease
Sponsor:
Abbott
Organization:
Abbott
Study Overview
Official Title:
A Multi-Center Randomized Double-Blind Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohns Disease
Status:
COMPLETED
Status Verified Date:
2007-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CHARM
Brief Summary:
The purpose of this study is to test whether Adalimumab at two different doses can induce and maintain clinical remission in subjects with active Crohns disease when compared to placebo a substance containing no medication
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None